Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D05FPZ
|
|||
Drug Name |
M7824
|
|||
Drug Type |
Antibody
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1], [2] | |
Company |
EMD SeronoRockland, MA
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Programmed cell death 1 ligand 1 (PD-L1) | Target Info | Inhibitor | [1] |
Programmed cell death protein 1 (PD-1) | Target Info | . | [3] | |
Transforming growth factor beta (TGFB) | Target Info | Inhibitor | [1] | |
KEGG Pathway | Cell adhesion molecules (CAMs) | |||
T cell receptor signaling pathway | ||||
Reactome | PD-1 signaling | |||
WikiPathways | Costimulation by the CD28 family | |||
T-Cell Receptor and Co-stimulatory Signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 3 | Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.